Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer

Purpose: We tested the hypothesis that allosteric Akt inhibitor MK-2206 inhibits tumor growth, and that PTEN/PIK3CA mutations confer MK-2206 sensitivity. Experimental Design: MK-2206 effects on cell signaling were assessed in vitro and in vivo. Its antitumor efficacy was assessed in vitro in a panel of cancer cell lines with differing PIK3CA and PTEN status. Its in vivo efficacy was tested as a single agent and in combination with paclitaxel. Results: MK-2206 inhibited Akt signaling and cell-cycle progression, and increased apoptosis in a dose-dependent manner in breast cancer cell lines. Cell lines with PTEN or PIK3CA mutations were significantly more sensitive to MK-2206; however, several lines with PTEN/PIK3CA mutations were MK-2206 resistant. siRNA knockdown of PTEN in breast cancer cells increased Akt phosphorylation concordant with increased MK-2206 sensitivity. Stable transfection of PIK3CA E545K or H1047R mutant plasmids into normal-like MCF10A breast cells enhanced MK-2206 sensitivity. Cell lines that were less sensitive to MK-2206 had lower ratios of Akt1/Akt2 and had less growth inhibition with Akt siRNA knockdown. In PTEN-mutant ZR75-1 breast cancer xenografts, MK-2206 treatment inhibited Akt signaling, cell proliferation, and tumor growth. In vitro, MK-2206 showed a synergistic interaction with paclitaxel in MK-2206–sensitive cell lines, and this combination had significantly greater antitumor efficacy than either agent alone in vivo. Conclusions: MK-2206 has antitumor activity alone and in combination with chemotherapy. This activity may be greater in tumors with PTEN loss or PIK3CA mutation, providing a strategy for patient enrichment in clinical trials. Clin Cancer Res; 18(20); 5816–28. ©2012 AACR.

[1]  A. Laenkholm,et al.  PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. , 2012 .

[2]  A. Laenkholm,et al.  PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Lucy Marum,et al.  Cancer Cell Line Encyclopedia launched by Novartis and Broad Institute. , 2012, Future medicinal chemistry.

[4]  G. Mills,et al.  PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors , 2012, Clinical Cancer Research.

[5]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[6]  J. Mayerle,et al.  The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. , 2012, Gastroenterology.

[7]  M. Xing,et al.  The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. , 2012, The Journal of clinical endocrinology and metabolism.

[8]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Liao,et al.  MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis , 2011, Molecular Cancer Therapeutics.

[10]  B. Wittner,et al.  Asymmetric cancer cell division regulated by AKT , 2011, Proceedings of the National Academy of Sciences.

[11]  K. Coombes,et al.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.

[12]  D. Coppola,et al.  Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice , 2011, Clinical Cancer Research.

[13]  G. Mills,et al.  PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer , 2011, Molecular Cancer Therapeutics.

[14]  Kuen-Feng Chen,et al.  Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells , 2011, Journal of Pharmacology and Experimental Therapeutics.

[15]  G. Robertson,et al.  eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. , 2011, Cancer research.

[16]  A. Toker,et al.  Akt2 regulates expression of the actin‐bundling protein palladin , 2010, FEBS letters.

[17]  Michael Peyton,et al.  Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo , 2010, PloS one.

[18]  G. Mills,et al.  Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer , 2010, Molecular Cancer Therapeutics.

[19]  G. Mills,et al.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.

[20]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[21]  A. Toker,et al.  The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. , 2010, Molecular cell.

[22]  Mingming Jia,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2009, Nucleic Acids Res..

[23]  S. Tsavachidis,et al.  The rapamycin-regulated gene expression signature determines prognosis for breast cancer , 2009, Molecular Cancer.

[24]  P. Pandolfi,et al.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. , 2009, Cancer cell.

[25]  Yiling Lu,et al.  AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.

[26]  G. Mills,et al.  Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.

[27]  T. McGraw,et al.  Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling , 2009, Proceedings of the National Academy of Sciences.

[28]  A. Toker,et al.  Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction , 2009, Nature Cell Biology.

[29]  Zhi Hu,et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.

[30]  F. Meric-Bernstam,et al.  Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. , 2007, Endocrine-related cancer.

[31]  L. Saal,et al.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair , 2008, Nature Genetics.

[32]  Yiling Lu,et al.  Pharmacodynamic Markers of Perifosine Efficacy , 2007, Clinical Cancer Research.

[33]  G. Mills,et al.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. , 2007, Cancer cell.

[34]  M. Ringnér,et al.  Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.

[35]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[36]  A. Newton,et al.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.

[37]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[38]  Brian A. Hemmings,et al.  Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 Binding , 2006, Molecular and Cellular Biology.

[39]  H. Koistinen,et al.  siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. , 2006, Cell metabolism.

[40]  Frank McCormick,et al.  High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.

[41]  Fred A. Wright,et al.  Practical FDR-based sample size calculations in microarray experiments , 2005, Bioinform..

[42]  T. Kawabe,et al.  Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.

[43]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[44]  G. Mills,et al.  Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[45]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[46]  G. Mills,et al.  Determinants of Rapamycin Sensitivity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[47]  L. Mulligan,et al.  Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. , 1999, The American journal of pathology.

[48]  L. Peso,et al.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.

[49]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[50]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .